p53 abnormalities are rare events in neuroendocrine (Merkel cell) carcinoma of the skin - An immunohistochemical and SSCP analysis

被引:17
作者
Schmid, M
Janssen, K
DockhornDworniczak, B
Metze, D
Zelger, BW
Luger, TA
Schmid, KW
机构
[1] UNIV MUNSTER, DERMATOL CLIN, D-48149 MUNSTER, GERMANY
[2] UNIV MUNSTER, CLIN OPHTHALMOL, D-48149 MUNSTER, GERMANY
[3] UNIV INNSBRUCK, DERMATOL CLIN, A-6020 INNSBRUCK, AUSTRIA
关键词
carcinogenesis; tumour development; tumour progression;
D O I
10.1007/BF01324807
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The aim of the present study was to assess a possible role of the tumour suppressor gene p53 in neuroendocrine (Merkel cell) carcinoma of the skin with regard to tumour development and tumour progression. p53 was investigated in a series of routinely processed Merkel cell carcinomas, with application of four different p53 antibodies (CM-1, PAb1801, DO7, and PAb240) to 25 carcinomas and screening for p53 mutations of exons 4-8 by single-strand conformation polymorphism (SSCP) analysis in 9 cases. All 25 tumours in the present series showed the characteristic microscopic and immunohistochemical features of Merkel cell carcinoma of the skin. In 5 of the 25 Merkel cell carcinomas investigated 5-10% of tumour cell nuclei showed a positive p53 reaction with at least one anti-p53 antibody. A few scattered p53 positive nuclei were found in an additional 9 cases. The remaining ii cases completely lacked p53 immunostaining. SSCP analysis of exons 4-8 revealed no significant alterations in the mobility shift of the single strand DNAs in the five cases with 5-10% p53-immunoreactive tumour nuclei or in five cases lacking p53 accumulation significant. Our results suggest that alterations of the p53 gene play only a minor part in the development or progression of Merkel cell carcinoma of the skin.
引用
收藏
页码:233 / 237
页数:5
相关论文
共 40 条
[1]  
ALLEN RC, 1989, BIOTECHNIQUES, V7, P736
[2]   WET AUTOCLAVE PRETREATMENT FOR ANTIGEN RETRIEVAL IN DIAGNOSTIC IMMUNOHISTOCHEMISTRY [J].
BANKFALVI, A ;
NAVABI, H ;
BIER, B ;
BOCKER, W ;
JASANI, B ;
SCHMID, KW .
JOURNAL OF PATHOLOGY, 1994, 174 (03) :223-228
[3]   ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT [J].
BARNES, DM ;
HANBY, AM ;
GILLETT, CE ;
MOHAMMED, S ;
HODGSON, S ;
BOBROW, LG ;
LEIGH, IM ;
PURKIS, T ;
MACGEOCH, C ;
SPURR, NK ;
BARTEK, J ;
VOJTESEK, B ;
PICKSLEY, SM ;
LANE, DP .
LANCET, 1992, 340 (8814) :259-263
[4]   IMMUNOHISTOCHEMICAL ANALYSIS OF THE P53 ONCOPROTEIN ON PARAFFIN SECTIONS USING A SERIES OF NOVEL MONOCLONAL-ANTIBODIES [J].
BARTEK, J ;
BARTKOVA, J ;
LUKAS, J ;
STASKOVA, Z ;
VOJTESEK, B ;
LANE, DP .
JOURNAL OF PATHOLOGY, 1993, 169 (01) :27-34
[5]  
BRINKSCHMIDT C, 1995, APPL IMMUNOHISTO M M, V3, P37
[6]  
CAMPBELL C, 1993, CANCER RES, V53, P2697
[7]  
CESARMAN E, 1993, AM J PATHOL, V143, P845
[8]  
DOCKHORNDWORNIC.B, 1993, EXP CLIN ENDOCRINOL, V101, P39
[9]  
ESRIG D, 1993, AM J PATHOL, V143, P1389
[10]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093